The ups and downs of pharmacopoeial harmonization
This article was originally published in Scrip
As drug regulation becomes more global in nature, international trade continues to expand, and drug substances are increasingly manufactured using biotechnology techniques, the European Pharmacopoeia Commission is taking steps to develop more harmonized international quality standards, and is also extending its reach to encompass the quality of finished products rather than just pharmaceutical substances.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.